IMMUNOVANT, INC. Operating Lease Right-of-Use Assets
IMMUNOVANT, INC. (IMVT) had Operating Lease Right-of-Use Assets of $72.00 thousand as of 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-05-20
- 2026-03-31: Operating Lease, Right-of-Use Asset $72.00K.
- 2025-03-31: Operating Lease, Right-of-Use Asset $98.00K.
- 2024-12-31: Operating Lease, Right-of-Use Asset $22.00K.
- 2024-09-30: Operating Lease, Right-of-Use Asset $45.00K.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-03-31 | $72.00K 10-K · filed 2026-05-20 | |
| 2025-03-31 | $98.00K 10-K · filed 2026-05-20 | |
| 2024-12-31 | $22.00K 10-Q · filed 2025-02-06 | |
| 2024-09-30 | $45.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $66.00K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $133.00K 10-K · filed 2025-05-29 | |
| 2023-12-31 | $294.00K 10-Q · filed 2024-02-12 | |
| 2023-09-30 | $589.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $882.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.17M 10-K · filed 2024-05-29 | |
| 2022-12-31 | $1.46M 10-Q · filed 2023-02-03 | |
| 2022-09-30 | $1.74M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $2.02M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $2.30M 10-K · filed 2023-05-22 | |
| 2021-12-31 | $2.45M 10-Q · filed 2022-02-04 | |
| 2021-09-30 | $2.73M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $3.01M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $3.28M 10-K · filed 2022-06-08 | |
| 2020-12-31 | $3.47M 10-Q · filed 2021-02-16 | |
| 2020-09-30 | $3.49M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $4.20M 10-K · filed 2021-06-01 | $4.06M 10-Q · filed 2020-08-12 |
| 2020-04-30 | $4.20M 10-Q · filed 2021-02-16 | |
| 2020-03-31 | $0.00 10-K · filed 2021-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |